HK1156624A1 - Crystalline forms of a 2-thiazolyl-4-quinolinyl-oxy derivative, a potent hcv inhibitor hcv 2--4-- - Google Patents

Crystalline forms of a 2-thiazolyl-4-quinolinyl-oxy derivative, a potent hcv inhibitor hcv 2--4--

Info

Publication number
HK1156624A1
HK1156624A1 HK11111031.5A HK11111031A HK1156624A1 HK 1156624 A1 HK1156624 A1 HK 1156624A1 HK 11111031 A HK11111031 A HK 11111031A HK 1156624 A1 HK1156624 A1 HK 1156624A1
Authority
HK
Hong Kong
Prior art keywords
hcv
quinolinyl
thiazolyl
crystalline forms
potent
Prior art date
Application number
HK11111031.5A
Other languages
English (en)
Chinese (zh)
Inventor
Thilo Berkenbusch
Carl Alan Busacca
Burkhard Jaeger
Richard J Varsolona
Original Assignee
貝林格爾．英格海姆國際有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41268627&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1156624(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 貝林格爾．英格海姆國際有限公司 filed Critical 貝林格爾．英格海姆國際有限公司
Publication of HK1156624A1 publication Critical patent/HK1156624A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HK11111031.5A 2008-09-16 2011-10-17 Crystalline forms of a 2-thiazolyl-4-quinolinyl-oxy derivative, a potent hcv inhibitor hcv 2--4-- HK1156624A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9729108P 2008-09-16 2008-09-16
US15082609P 2009-03-09 2009-03-09
PCT/US2009/056772 WO2010033444A1 (en) 2008-09-16 2009-09-14 Crystalline forms of a 2-thiazolyl- 4-quinolinyl-oxy derivative, a potent hcv inhibitor

Publications (1)

Publication Number Publication Date
HK1156624A1 true HK1156624A1 (en) 2012-06-15

Family

ID=41268627

Family Applications (1)

Application Number Title Priority Date Filing Date
HK11111031.5A HK1156624A1 (en) 2008-09-16 2011-10-17 Crystalline forms of a 2-thiazolyl-4-quinolinyl-oxy derivative, a potent hcv inhibitor hcv 2--4--

Country Status (34)

Country Link
US (2) US8232293B2 (me)
EP (2) EP2331538B1 (me)
JP (2) JP5520301B2 (me)
KR (1) KR101653550B1 (me)
CN (1) CN102159571B (me)
AR (1) AR073298A1 (me)
AU (1) AU2009293494B2 (me)
BR (1) BRPI0918513A2 (me)
CA (1) CA2737055C (me)
CL (1) CL2011000558A1 (me)
CO (1) CO6351741A2 (me)
CY (1) CY1115253T1 (me)
DK (1) DK2331538T3 (me)
EA (1) EA018603B1 (me)
EC (1) ECSP11010878A (me)
ES (1) ES2474992T3 (me)
HK (1) HK1156624A1 (me)
HR (1) HRP20140666T1 (me)
IL (1) IL210345A (me)
MA (1) MA32633B1 (me)
ME (1) ME01831B (me)
MX (1) MX2011002828A (me)
MY (1) MY153093A (me)
NZ (2) NZ602163A (me)
PE (2) PE20110388A1 (me)
PL (1) PL2331538T3 (me)
PT (1) PT2331538E (me)
RS (1) RS53292B (me)
SG (1) SG189740A1 (me)
SI (1) SI2331538T1 (me)
TW (1) TWI471323B (me)
UY (1) UY32119A (me)
WO (1) WO2010033444A1 (me)
ZA (1) ZA201100096B (me)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
NZ602163A (en) 2008-09-16 2013-06-28 Boehringer Ingelheim Int Crystalline forms of a 2-thiazolyl- 4-quinolinyl-oxy derivative, a potent hepatitis c viral inhibitor
BRPI0918653A2 (pt) 2008-09-17 2015-12-01 Boehringer Ingelheim Int combinação de inibidor de ns3 protese de hcv com interferon e ribavirina.
EP2408382A4 (en) * 2009-03-13 2013-06-19 Univ Toledo MINIMALLY INVASIVE COLLABBABLE CAGE
CA2753657A1 (en) * 2009-03-19 2010-09-23 Boehringer Ingelheim International Gmbh Process for preparing sulfonyl quinolines
US8633320B2 (en) 2009-05-05 2014-01-21 Boehringer Ingelheim International Gmbh Process for preparing bromo-substituted quinolines
MA33491B1 (fr) 2009-07-07 2012-08-01 Boehringer Ingelheim Int Composition pharmaceutique pour un inhibiteur de protease virale de l'hépatite c
EA201200650A1 (ru) 2009-10-30 2012-12-28 Бёрингер Ингельхайм Интернациональ Гмбх Курсы комбинированного лечения вируса гепатита с, включающие bi201335, интерферон-альфа и рибавирин
US8530497B2 (en) 2010-03-11 2013-09-10 Boehringer Ingelheim International Gmbh Crystalline salts of a potent HCV inhibitor
MX2013003060A (es) 2010-09-30 2013-05-30 Boehringer Ingelheim Int Terapia de combinacion para tratar infeccion por hcv.
JP2014502620A (ja) 2010-12-30 2014-02-03 エナンタ ファーマシューティカルズ インコーポレイテッド 大環状ｃ型肝炎セリンプロテアーゼ阻害剤
CN103380132B (zh) 2010-12-30 2016-08-31 益安药业 菲啶大环丙型肝炎丝氨酸蛋白酶抑制剂
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
CN104023726A (zh) 2011-10-21 2014-09-03 艾伯维公司 用于治疗hcv的一种或多种daa的联合治疗(例如，与abt-072或abt-333)
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
UY34402A (es) 2011-10-21 2013-05-31 Abbvie Inc Métodos para el tratamiento de hcv
SG11201404042VA (en) 2012-01-12 2014-08-28 Boehringer Ingelheim Int Stabilized pharmaceutical formulations of a potent hcv inhibitor
WO2013137869A1 (en) 2012-03-14 2013-09-19 Boehringer Ingelheim International Gmbh Combination therapy for treating hcv infection in an hcv-hiv coinfected patient population
WO2013147749A1 (en) 2012-03-27 2013-10-03 Boehringer Ingelheim International Gmbh Oral combination therapy for treating hcv infection in specific patient subgenotype populations
WO2013147750A1 (en) 2012-03-27 2013-10-03 Boehringer Ingelheim International Gmbh Oral combination therapy for treating hcv infection in specific patient sub-population
JP2015512900A (ja) 2012-03-28 2015-04-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 特別な患者の遺伝子亜型分集団のｈｃｖ感染症を治療するための併用療法
UA119315C2 (uk) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с
WO2014138374A1 (en) 2013-03-08 2014-09-12 Boehringer Ingelheim International Gmbh Oral combination therapy for treating hcv infection in specific patient sub-population
EA029088B1 (ru) 2013-03-15 2018-02-28 Джилид Сайэнс, Инк. Макроциклические и бициклические ингибиторы вируса гепатита c
AU2014233705C1 (en) * 2013-03-15 2019-10-10 Boehringer Ingelheim International Gmbh Solid oral dosage formulation of HCV inhibitor in the amorphous state
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
US11192914B2 (en) 2016-04-28 2021-12-07 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
WO2022107182A1 (en) * 2020-11-18 2022-05-27 University Of Petra A composition of fentanyl and fatty acids, and a method of preparation thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2308955T5 (es) 1993-09-28 2012-04-03 R.P. Scherer Gmbh Fabricación de cápsulas de gelatina blanda
AR022061A1 (es) 1998-08-10 2002-09-04 Boehringer Ingelheim Ca Ltd Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos.
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
US6608027B1 (en) 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
UA74546C2 (en) 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
CA2396079A1 (en) * 2000-01-07 2001-07-19 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
UY28240A1 (es) * 2003-03-27 2004-11-08 Boehringer Ingelheim Pharma Fases cristalinas de un potente inhibidor de la hcv
KR101115294B1 (ko) * 2003-05-21 2012-04-12 베링거 인겔하임 인터내셔날 게엠베하 Ｃ형 간염 억제제 화합물
CA2568008C (en) * 2004-05-25 2014-01-28 Boehringer Ingelheim International Gmbh Process for preparing acyclic hcv protease inhibitors
NZ602163A (en) * 2008-09-16 2013-06-28 Boehringer Ingelheim Int Crystalline forms of a 2-thiazolyl- 4-quinolinyl-oxy derivative, a potent hepatitis c viral inhibitor
US8530497B2 (en) 2010-03-11 2013-09-10 Boehringer Ingelheim International Gmbh Crystalline salts of a potent HCV inhibitor

Also Published As

Publication number Publication date
EP2331538B1 (en) 2014-04-16
JP5520301B2 (ja) 2014-06-11
EA201100482A1 (ru) 2011-10-31
MX2011002828A (es) 2011-04-05
EP2687526A1 (en) 2014-01-22
CY1115253T1 (el) 2017-01-04
AR073298A1 (es) 2010-10-28
EP2331538A1 (en) 2011-06-15
US20100093792A1 (en) 2010-04-15
PL2331538T3 (pl) 2014-09-30
CL2011000558A1 (es) 2011-07-15
TWI471323B (zh) 2015-02-01
US8232293B2 (en) 2012-07-31
IL210345A0 (en) 2011-03-31
NZ602163A (en) 2013-06-28
US8362035B2 (en) 2013-01-29
SG189740A1 (en) 2013-05-31
DK2331538T3 (da) 2014-06-02
UY32119A (es) 2010-04-30
KR101653550B1 (ko) 2016-09-02
ME01831B (me) 2014-12-20
BRPI0918513A2 (pt) 2015-12-01
CN102159571A (zh) 2011-08-17
SI2331538T1 (sl) 2014-06-30
CO6351741A2 (es) 2011-12-20
WO2010033444A1 (en) 2010-03-25
WO2010033444A8 (en) 2010-06-17
US20120270775A1 (en) 2012-10-25
ES2474992T3 (es) 2014-07-10
MA32633B1 (fr) 2011-09-01
TW201024292A (en) 2010-07-01
IL210345A (en) 2015-06-30
CA2737055C (en) 2016-08-30
PT2331538E (pt) 2014-05-12
ECSP11010878A (es) 2011-07-29
AU2009293494A1 (en) 2010-03-25
NZ591013A (en) 2012-09-28
PE20130307A1 (es) 2013-03-22
KR20110059841A (ko) 2011-06-07
AU2009293494B2 (en) 2014-04-24
JP2012502910A (ja) 2012-02-02
RS53292B (en) 2014-08-29
JP2014062116A (ja) 2014-04-10
PE20110388A1 (es) 2011-07-01
EA018603B1 (ru) 2013-09-30
CA2737055A1 (en) 2010-03-25
MY153093A (en) 2014-12-31
ZA201100096B (en) 2011-09-28
HRP20140666T1 (hr) 2014-10-10
CN102159571B (zh) 2014-10-01

Similar Documents

Publication Publication Date Title
HK1156624A1 (en) Crystalline forms of a 2-thiazolyl-4-quinolinyl-oxy derivative, a potent hcv inhibitor hcv 2--4--
LT2155200T (lt) Karbamoil-cikloheksano darinio kristalinė forma
HK1205125A1 (en) Polymorphic forms of a macrocyclic inhibitor of hcv hcv
IL221123A (en) Powerful polythrocyclic compounds as hcv inhibitors
HK1200440A1 (zh) 種抑制劑的結晶形式
GB0819182D0 (en) Crystalline forms
IL196706A0 (en) Crystalline forms of rapamycin analogs
IL221198A0 (en) Crystalline salts of a potent hcv inhibitor
HK1164698A1 (en) Crystalline forms of genistein
HK1124068A1 (en) 2-arylindole derivatives as mpges-1 inhibitors
SI2358676T1 (sl) Kristalinična oblika 4-(2-(2-fluorofenoksimetil)fenil)piperidinske spojine
ZA201100999B (en) Synthesis of a crystalline silicoaluminophosphate
PT2343292E (pt) Novo derivado de prostaglandina i2
ZA200903614B (en) New crystalline forms
ZA201104319B (en) Crystalline forms of a 3-carboxypropyl-aminotetralin compound
AP2013006733A0 (en) Solid state forms of a potent HCV inhibitor
IL210777A0 (en) Crystalline forms of a pyridine derivative
IL208543A (en) History of the eupyrpine peptide as potent inhibitors of encephalin-actopeptidase joint
EP1983997A4 (en) CRYSTALLINE FORMS OF A FARNESYL DIBENZODIAZEPINONE
ZA200900740B (en) Crystalline forms of rapamycin analogs
HU0800755D0 (en) Novel crystalline forms
IL213288A0 (en) Crystalline forms
GB0817164D0 (en) Crystalline forms

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20210914